Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review
Aims To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).Methods We report two cases of refractory PG treated with canakinumab after failing multiple therapies.Results A 44-year-old female achieved complete ulcer resolution after 31 months of cana...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2495834 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850171651786801152 |
|---|---|
| author | Howard Jie Yang William Spratt Francis Yi Xing Lai Senhong Lee |
| author_facet | Howard Jie Yang William Spratt Francis Yi Xing Lai Senhong Lee |
| author_sort | Howard Jie Yang |
| collection | DOAJ |
| description | Aims To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).Methods We report two cases of refractory PG treated with canakinumab after failing multiple therapies.Results A 44-year-old female achieved complete ulcer resolution after 31 months of canakinumab but experienced recurrent infections, including pneumonia requiring intensive care unit (ICU) admission. A 49-year-old male showed no improvement and suffered recurrent Pseudomonas infections, leading to treatment cessation after nine months.Conclusions We present a case series of two patients with PG on canakinumab therapy, both of whom experienced significant infections needing hospitalization. Further studies are needed to evaluate the efficacy and complication profile of canakinumab against other biologic therapy options. |
| format | Article |
| id | doaj-art-b5ad708cfb3545d5a3b7666e8f546ffa |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-b5ad708cfb3545d5a3b7666e8f546ffa2025-08-20T02:20:15ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2495834Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature reviewHoward Jie Yang0William Spratt1Francis Yi Xing Lai2Senhong Lee3Department of Dermatology, Monash Health, Clayton, AustraliaDepartment of Dermatology, Monash Health, Clayton, AustraliaDepartment of Dermatology, Monash Health, Clayton, AustraliaDepartment of Dermatology, Monash Health, Clayton, AustraliaAims To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).Methods We report two cases of refractory PG treated with canakinumab after failing multiple therapies.Results A 44-year-old female achieved complete ulcer resolution after 31 months of canakinumab but experienced recurrent infections, including pneumonia requiring intensive care unit (ICU) admission. A 49-year-old male showed no improvement and suffered recurrent Pseudomonas infections, leading to treatment cessation after nine months.Conclusions We present a case series of two patients with PG on canakinumab therapy, both of whom experienced significant infections needing hospitalization. Further studies are needed to evaluate the efficacy and complication profile of canakinumab against other biologic therapy options.https://www.tandfonline.com/doi/10.1080/09546634.2025.2495834Pyoderma gangrenosumcanakinumabadverse eventsinterleukin inhibitors |
| spellingShingle | Howard Jie Yang William Spratt Francis Yi Xing Lai Senhong Lee Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review Journal of Dermatological Treatment Pyoderma gangrenosum canakinumab adverse events interleukin inhibitors |
| title | Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review |
| title_full | Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review |
| title_fullStr | Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review |
| title_full_unstemmed | Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review |
| title_short | Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review |
| title_sort | canakinumab for the management of pyoderma gangrenosum a case series of two patients and literature review |
| topic | Pyoderma gangrenosum canakinumab adverse events interleukin inhibitors |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2495834 |
| work_keys_str_mv | AT howardjieyang canakinumabforthemanagementofpyodermagangrenosumacaseseriesoftwopatientsandliteraturereview AT williamspratt canakinumabforthemanagementofpyodermagangrenosumacaseseriesoftwopatientsandliteraturereview AT francisyixinglai canakinumabforthemanagementofpyodermagangrenosumacaseseriesoftwopatientsandliteraturereview AT senhonglee canakinumabforthemanagementofpyodermagangrenosumacaseseriesoftwopatientsandliteraturereview |